The British Association of Urological Surgeons (BAUS) has honored Mark Soloway, M.D., Chief of Urologic Oncology at Memorial Cancer Institute, with the association’s highest award for contributions to the field of Urology – The St. Paul’s Medal for 2015.
Among his contributions to the treatment of bladder, prostate and kidney cancer, Dr. Soloway has been associated with being instrumental in recognizing the benefit of chemotherapeutic drug, Cisplatin, for its anticancer activity in bladder cancer 40 years ago. It remains the most active treatment for advanced bladder cancer. He has also been instrumental in helping to define the role of placing drugs inside the bladder for the treatment of early stage bladder cancer to diminish the chance of a local recurrence. He has championed the role of active surveillance or forgoing aggressive treatment for low grade bladder and prostate cancer resulting in quality of life improvement for patients. He has also published over 530 papers in peer-reviewed journals.
Dr. Soloway, who joined the Memorial Cancer Institute and the Memorial Physician Group in 2014, leads a new division focused on the care of bladder, prostate and kidney cancers, as well as the research program. He regularly treats patients at Memorial Cancer Institute offices in Aventura and Boca Raton. Dr. Soloway also serves as a resource to other community urologists, providing second opinions regarding management and alternatives for the most common urologic cancers.
